Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | SVP Finance, CAO | February 03, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date February 03, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.91 · Expires 2036-02-03 | Direct | 140,000 |
Reported balance
After 2026-02-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-03 · Grant · Acquired 140,000 · Balance 140,000 F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2026 Filed Feb 5, 2026 13:22 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 140,000 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001790340-26-000026 · wk-form4_1770297748.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · SVP Finance, CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Class A Common Stock · 140,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2026, and will be fully vested and exercisable on January 1, 2030. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 13:02 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 300 | $6.39 | $1,917.00 |
DisclosureSEC source: 0001790340-25-000125 · wk-form4_1759410175.xml · nonDerivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,533 Read SEC document |
| September 15, 2025 Filed Sep 17, 2025 20:35 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 14,497 | $1.43 | $20,701.72 |
DisclosureSEC source: 0001790340-25-000113 · wk-form4_1758141356.xml · nonDerivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,233 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 16, 2025 through September 15, 2025. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2025. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of the relevant Offering Period. Read SEC document |
| February 05, 2025 Filed Feb 7, 2025 21:25 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 110,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001790340-25-000032 · wk-form4_1738963510.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2035-02-05 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2025, and will be fully vested and exercisable on January 1, 2029. Read SEC document |
| September 15, 2024 Filed Sep 17, 2024 20:09 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 4,458 | $1.62 | $7,237.56 |
DisclosureSEC source: 0001790340-24-000071 · wk-form4_1726603736.xml · nonDerivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,736 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of March 15, 2024 through September 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of September 15, 2024. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Enrollment Date (as defined in the ESPP) of March 15, 2024. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 72,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 12 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Class A Common Stock · 72,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 72,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 11 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 72,000 shares Expires 2033-02-15 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F7 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 10 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 9 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F6 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 8 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-06-13 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 15,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 7 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 15,000 shares Expires 2033-06-13 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F5 · derivative.exercise_date: The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 5,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 6 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Class A Common Stock · 5,000 shares Expires 2032-06-30 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on July 31, 2022, and will be fully vested and exercisable on June 30, 2026. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 5,000 | $0.00 Strike: $5.41 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 5 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 5,000 shares Expires 2032-06-30 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F4 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on July 31, 2022, and will be fully vested and exercisable on June 30, 2026. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 23,850 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 4 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,850 Underlying: Class A Common Stock · 23,850 shares Expires 2032-02-10 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 23,850 | $0.00 Strike: $9.66 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 3 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 23,850 shares Expires 2032-02-10 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F3 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 2 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2032-08-11 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| May 21, 2024 Filed May 23, 2024 20:18 UTC | Immuneering Corp IMRX · Entity 5884 | Disposition to issuerStock Option · Derivative | 10,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001628280-24-024950 · wk-form4_1716495475.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 10,000 shares Expires 2032-08-11 F1 · kind: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F1 · price: On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 13:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 393 | $2.55 | $1,000.38 |
DisclosureSEC source: 0001790340-24-000038 · wk-form4_1711371878.xml · nonDerivative · entry 3 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,278 Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 13:04 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 1,107 | $2.72 | $3,008.72 |
DisclosureSEC source: 0001790340-24-000038 · wk-form4_1711371878.xml · nonDerivative · entry 2 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,885 F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.675 to $2.74. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price. Read SEC document |
| March 15, 2024 Filed Mar 25, 2024 13:04 UTC | Immuneering Corp IMRX · Entity 5884 | GrantClass A Common Stock | 4,344 | $1.62 | $7,037.28 |
DisclosureSEC source: 0001790340-24-000038 · wk-form4_1711371878.xml · nonDerivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,778 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's Class A Common Stock pursuant to the Immuneering Corporation 2021 Employee Stock Purchase Plan (the "ESPP"), for the ESPP purchase period of September 15, 2023 through March 15, 2024. This transaction is also exempt pursuant to Rule 16b-3(c) promulgated pursuant to the Securities Exchange Act of 1934. F2 · date: The relevant Offering Period (as defined in the ESPP) ended, and the shares were acquired, on the Purchase Date (as defined in the ESPP) of March 15, 2024. F3 · price: In accordance with the ESPP, the shares were purchased at a price not less than eighty-five percent (85%) of the Fair Market Value (as defined in the ESPP) of a share of Class A Common Stock on the Purchase Date of March 15, 2024. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 21:30 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 60,500 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001790340-24-000016 · wk-form4_1707514195.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,500 Underlying: Class A Common Stock · 60,500 shares Expires 2034-02-08 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028. Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001790340-23-000027 · wk-form4_1686773684.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · VICE PRESIDENT, FINANCE 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) substantially equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:30 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 72,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001415889-23-002773 · form4-02172023_090206.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · VICE PRESIDENT, FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,000 Underlying: Class A Common Stock · 72,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027. Read SEC document |
| August 11, 2022 Filed Aug 12, 2022 20:15 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $6.33 | $0.00 |
DisclosureSEC source: 0001415889-22-008536 · form4-08122022_040801.xml · derivative · entry 1 Morales Mallory · CIK 0001941795 · VICE PRESIDENT, FINANCE 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2032-08-11 F1 · derivative.exercise_date: 100% of the option vests and becomes exercisable on August 11, 2023, subject Ms. Morales' continued employment through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.